Press Releases

Vent Multiplexor, LLC and Yale New Haven Hospital announced today that the Food and Drug Administration has granted Emergency Use Authorization for the Vent Multiplexor, a life-saving emergency rescue device developed by Vent Multiplexor LLC in collaboration with Yale New Haven Hospital. The Vent Multiplexor is a patent-pending device designed to provide individualized emergency crisis care for two adult patients requiring mechanical ventilation when limited to a single mechanical ventilator.

As the COVID-19 pandemic is swiftly spreading around the globe and gaining a grip in India, and hence the need for rapid diagnosis is increased tremendously. Diagnosis is critical not only at the single-patient level to regulate future treatment, but also to identify carriers at the population level, isolate them and thereby prevent further spread of the disease. Due to shortage supply of kits which are becoming scarce as demand rises globally all of a sudden, ICRM released an advis

Synapse Biomedical, Inc. has received FDA Emergency Use Authorization for the emergency use of its TransAeris® DPS, to assist in weaning patients determined by their healthcare provider to be at high risk of weaning failure off of ventilators in healthcare settings during the COVID-19 pandemic for no more than 30 days. During the COVID-19 pandemic, the surge of patients requiring prolonged mechanical ventilation (PMV) has put an unprecedented demand on hospital and ICU resources

Xenocor, Inc. announced the FDA cleared the new Xenocor Disposable 5mm Articulating Laparoscope for minimally invasive abdominal and thoracic surgery. The Xenoscope 5mm articulating disposable laparoscope is designed to improve image quality, reduce fog, lower hospital costs, and reduce bio-hazard risk for the patient and staff.   "Disposable laparoscopes can reduce hospital costs and prevent cross-contamination between patients," said John Langell MD, President, NEOM

VUNO, a member company of the Born2Global Centre, announced that their AI based screening solution for the fundus, VUNO Med®-Fundus AI™ is approved as a Class III medical device by the Ministry of Food and Drug Safety. VUNO Med®-Fundus AI™ is the first ever AI device to gain a Class III approval in Korea and is clinically validated to provide highly accurate screening results. According to the research paper published in Ophthalmology, one of the most prestigious

Abbott announced that its TriClip™ Transcatheter Tricuspid Valve Repair System has received CE Mark and is now approved for use in Europe and other countries that recognize CE Mark as a non-surgical treatment for people with a leaky tricuspid valve, a condition known as tricuspid regurgitation (TR). With the CE Mark designation, Abbott's TriClip device is the first minimally invasive, clip-based tricuspid valve repair device to be commercially available in the world. Abbott is a glo

NEW YORK, March 4, 2020 /PRNewswire/ -- Corporate Insight, the leading provider of competitive intelligence and user experience research, today announced the release of its new Medicare Monitor. This service benchmarks all aspects of the digital user experience for Medicare plan prospects and members, from account opening and onboarding to the secure customer web a

SHANGHAI, March. 4, 2020 /PRNewswire/ -- Luye Pharma Group has announced that the U.S. Food and Drug Administration (FDA) has reviewed and accepted the filing of a New Drug Application (NDA) for LY03005, a new chemical drug for the treatment of major depressive disorder. LY03005 is the company's second drug in the central nervous system (CNS) therapeutic area currently in the U.S. FDA's NDA phase.

NEW YORK, March 4, 2020 /PRNewswire/ -- On Tuesday, March 3, 2020, the Pasteur Foundation US honored three individuals with its prestigious awards during a special gala. Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson, received the inaugural

CONCORD, Mass., March 4, 2020 /PRNewswire/ -- Alopexx Oncology, LLC announced today that it has entered into an exclusive license agreement with Beijing Shenogen Pharma Group to develop and commercialize DI-Leu16-IL2 in China and other parts of Asia.  Alopexx will receive an upfront payment, variou